Ultragenyx Pharmaceutical (RARE) Change in Receivables (2018 - 2026)

Ultragenyx Pharmaceutical (RARE) has reported Change in Receivables for 9 consecutive years, with -$19.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Receivables fell 90.0% year-over-year to -$19.0 million; the TTM figure through Mar 2026 stood at $22.0 million (up 2522.91% YoY), while the FY2025 annual figure was $31.0 million, down 8.82% from the prior year.
• Change in Receivables retreated to -$19.0 million in Q1 2026 per RARE's latest filing, from $33.8 million in the prior quarter.
• Across five years, Change in Receivables topped out at $33.8 million in Q4 2025 and bottomed at -$19.0 million in Q1 2026.
• Historically, Change in Receivables has averaged $4.8 million across 5 years, with a median of $2.5 million in 2023.
• Annual changes were most pronounced in 2022 — Change in Receivables sank 955.56% — and 2023, when it soared 7700.0%.
• Ultragenyx Pharmaceutical's Change in Receivables stood at $9.1 million in 2022, then slumped by 108.69% to -$790000.0 in 2023, then soared by 2763.54% to $21.0 million in 2024, then surged by 60.79% to $33.8 million in 2025, then sank by 156.16% to -$19.0 million in 2026.
• Business Quant data shows RARE's Change in Receivables at -$19.0 million in Q1 2026, $33.8 million in Q4 2025, and -$5.4 million in Q3 2025.